Global Acute Dystonia Market, By Drug Class (Anticholinergic Agents, Benzodiazepines, Others), By Age Group (Children, Adult), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia P

Global Acute Dystonia Market, By Drug Class (Anticholinergic Agents, Benzodiazepines, Others), By Age Group (Children, Adult), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).


The global acute dystonia market was valued US$ 120.7 Mn in 2023 and is expected to reach US$ 155.0 Mn by 2031 growing at a compound annual growth rate (CAGR) of 3.2% from 2024 to 2031.

Figure 1. Global Acute Dystonia Market Share (%), By Region, 2024

Acute dystonia is a movement disorder characterized by involuntary muscle contractions that lead to repetitive movements or abnormal postures. These contractions can be painful and are often caused by a sudden onset of muscle spasms. Acute dystonia can affect any part of the body, including the neck (cervical dystonia), eyes (oculogyric crisis), jaw or tongue, and the limbs. The condition can have varying causes, including:
  • Drug-induced Dystonia: One of the most common causes. It can occur as a side effect of certain medications, particularly antipsychotic drugs that affect dopamine pathways in the brain.
  • Idiopathic Dystonia: Where the cause is unknown
  • Secondary Dystonia: Resulting from an underlying medical condition such as Wilson's disease, Huntington's disease, Parkinson's disease, brain injury, or stroke
Market Dynamics:

The global acute dystonia market is driven by the rising prevalence of neurological disorders that can induce acute dystonia like Parkinson's disease, cerebral palsy, and tardive dyskinesia. For instance, on August 9, 2023, according to a report published by the World Health Organization (WHO), Parkinson’s disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain, and other health issues. Nearly one million people in the U.S. were living with Parkinson's disease (PD) in 2021, while this number is expected to rise to 1.2 million by 2030. Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's disease.

Furthermore, in March 2022, according to a report published by the National Center for Biotechnology Information, cerebral palsy occurs in 2.3 to 3.6 out of every 1,000 children in the U.S., every year. While spastic cerebral palsy is the most common, making up 61 percent to 76.9 percent of all cerebral palsy cases.

Key Features of the Study:
  • This report provides an in-depth analysis of the global acute dystonia market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2024–2031), considering 2023 as the base year
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global acute dystonia market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Fresenius Kabi, Amar Healthcare, Johnson & Johnson ,PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc. , Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global acute dystonia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute dystonia market
Detailed Segmentation:
  • Global Acute Dystonia Market, By Drug Class
  • Anticholinergic Agents
  • Benzodiazepines
  • Others (Neurotoxin, etc.)
  • Global Acute Dystonia Market, By Age Group
  • Children
  • Adult
  • Global Acute Dystonia Market, By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Acute Dystonia Market, By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • Top Companies in the Global Acute Dystonia Market:
  • Fresenius Kabi
  • Amar Healthcare
  • Johnson & Johnson
  • PAI Pharma
  • Pfizer Inc.
  • Souvin Pharmaceuticals Pvt.Ltd
  • Bayer Healthcare
  • S.Pharmachem
  • Remedy Labs
  • Wan Bury
  • F.Hoffmann-La Roche Ltd
  • Bausch Health Companies, Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd.
  • Mallinckrodt Pharmaceuticals
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Age Group
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Increasing prevalence of dystonia
Side effects associated with drugs
Understanding changing treatment patterns
Key Highlights
Regulatory Guidelines
Market Trends
PEST Analysis
Investments and Funding
Mergers, Acquisitions, and Collaborations
Product Mapping
Identification of Top Market Players
Adoption of Various Business Development Strategies by the Market players
Healthcare Spending by Country
4. Global Acute Dystonia Market – Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Acute Dystonia Market, By Drug Class, 2019-2031, (US$ Mn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 – 2031
Segment Trends
Anticholinergic Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Benzodiazepines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Others (Neurotoxin, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
6. Global Acute Dystonia Market, By Age Group, 2019-2031, (US$ Mn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 – 2031
Segment Trends
Children
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Adult
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
7. Global Acute Dystonia Market, By Distribution Channel, 2019-2031, (US$ Mn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 – 2031
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031,(US$ Mn)
8. Global Acute Dystonia Market, By Region, 2019-2031, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2024 and 2031 (%)
Y-o-Y Growth Analysis, For Region, 2020 – 2031
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
U.S.
Canada
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
Brazil
Argentina
Mexico
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2019-2031,(US$ Mn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019-2031,(US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019-2031,(US$ Mn)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Company Profile
Fresenius Kabi
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Amar Healthcare
Johnson & Johnson
PAI Pharma
Pfizer Inc.
Souvin Pharmaceuticals Pvt.Ltd
Bayer Healthcare
S.Pharmachem
Remedy Labs
Wan Bury
Hoffmann-La Roche Ltd
Bausch Health Companies, Inc.
Viatris Inc.
Teva Pharmaceutical Industries Ltd
Torrent Pharmaceuticals Ltd.
Mallinckrodt Pharmaceuticals
Amneal Pharmaceuticals LLC
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma Ltd.
Analyst Views
10. Section
References
Research Methodology
About us
*Browse 39 market data tables and 32 figures on “Global Acute Dystonia Market” - Global forecast to 2031

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings